Yi Yang

Yi Yang

Auto-generated profile, based on publicly available information

Yi Yang

Department of Radiation Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
YYYi Yang
Yi Yang
QCQing Chen
Qing Chen
HPHai‐Yan Piao
Hai‐Yan Piao
BWBiao Wang
Biao Wang
GZGui‐Qi Zhu
Gui‐Qi Zhu
ZDZhi Dai
Zhi Dai

18 March 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ZCZongyou Chen
Zongyou Chen
YZYiwen Zang
Yiwen Zang
YYYi Yang
Yi Yang
JXJianbin Xiang
Jianbin Xiang
ZCZongyou Chen
Zongyou Chen
Colon cancer is one of the most malignant cancers worldwide. Nearly 20% of all colon cancer patients are diagnosed at stage IV (metastasis). However, further study of colon cancer is difficult due to a lack of understanding of its pathogenesis. In this study, we acquired high–throughput sequence data from TCGA datasets and performed integrated bioinformatic analysis including differential gene expression analysis, gene ontology and KEGG pathways analysis, protein–protein analysis, survival analysis, and multivariate Cox proportional hazards regression analysis in order to identify a panel of key candidate genes involved in the metastasis of colon cancer. We then constructed a prognostic signature based on the expression of REG1B, TGM6, NTF4, PNMA5, and HOXC13 which could provide significant prognostic value for colon cancer.

27 August 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YYYi Yang
Yi Yang
XCXue-Qin Chen
Xue-Qin Chen
YJYa-Xun Jia
Ya-Xun Jia
JMJie Ma
Jie Ma
DXDi Xu
Di Xu
ZXZuo-Lin Xiang
Zuo-Lin Xiang
Lymph node metastasis (LNM) is a common invasive feature of hepatocellular carcinoma (HCC) associated with poor clinical outcomes. Through microarray profiling and bioinformatic analyses, we identified the circ-0044539-miR-29a-3p-VEGFA axis as a potential key factor in the progression of HCC LNM. In HCC cells and nude mice, circ-0044539 downregulation or miR-29a-3p upregulation was associated with small tumor size, PI3K-AKT-mTOR pathway inactivation, and downregulation of the key LNM factors (HIF-1α and CXCR4). Furthermore, circ-0044539 was also responsible for exosomal miR-29a-3p secretion. Exosomal miR-29a-3p was then observed to migrate to the LNs and downregulate High-mobility group box transcription factor 1 (Hbp1) in Polymorphonuclear Myeloid-derived suppressor cells (PMN-MDSCs), inducing the formation of a microenvironment suitable for tumor colonization. Overall, circ-0044539 promotes HCC cell LNM abilities and induces an immune-suppressive environment in LNs through exosomes, highlighting its potential as a target for HCC LNM and HCC immunotherapy.

1 December 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
GZGui-Qi Zhu
Gui-Qi Zhu
KWKang Wang
Kang Wang
BWBiao Wang
Biao Wang
YZYu-Jie Zhou
Yu-Jie Zhou
YYYi Yang
Yi Yang
ZDZhi Dai
Zhi Dai
Background and aim: To investigate the value of the aspartate aminotransferase-to-platelet ratio index (APRI) and build a new nomogram for hepatocellular carcinoma (HCC) patients undergoing postoperative adjuvant transarterial chemoembolization (PATACE). Methods: We retrospectively reviewed 351 patients with HCC undergoing PATACE. We collected baseline HCC patient characteristics to obtain the risk factors for determining poor disease-free survival (DFS) and early time to recurrence (TTR) after PATACE. The multivariate Cox proportional hazards model was used to build new nomogram based on significant prognostic factors of outcomes. Results: We generated the cutoff value of the APRI as 0.50 using the X-tile to distinguish patients with different outcomes in the whole cohort. Two hundred seventeen patients with high APRI had poorer survival (P<0.001) than did 134 patients with low APRI. Furthermore, a nomogram, including tumor size, alanine aminotransferase (ALT) level, white blood cell counts, Barcelona Clinic Liver Cancer grade, and APRI was built for DFS, while factors including hepatitis B surface antigen, tumor size, ALT, microvascular invasion, and APRI was built for TTR. Internal validation with 500 bootstrapped sample sets had a good concordance index of 0.729 for DFS and 0.730 for TTR. Additionally, nomogram based on APRI conferred more prognostic value than previous biomarkers. Conclusion: High APRI was associated with worse survival and shorter TTR for HCC patients undergoing PATACE. This simple nomogram based on APRI conferred personalized survival and recurrence data for HCC patients undergoing PATACE.